Video

Advancing Cell Therapy Toward a Functional Cure for T1D With Forthcoming BetaNova's Jonathan Rigby and Will Rust, Ph.D.

Source: Cell & Gene

On episode 139, Host Erin Harris talks to Jonathan Rigby, President and CEO of Sernova (and proposed CEO of BetaNova) and Will Rust, PhD, President and CEO of Seraxis (and proposed President and Chief Scientific Officer of BetaNova). Sernova and Seraxis are coming together to form BetaNova, combining Sernova’s implantable Cell Pouch with Seraxis’ stem cell-derived pancreatic islet cells in an effort to develop a functional cell therapy for people living with Type 1 diabetes (T1D).

Access The Video!

Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.

Subscribe to Cell & Gene X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Cell & Gene

Please tell us more about you so that we can customize our newsletters to your specific interests:

What topics interest you? (Check all that apply.)